MARKET WIREYahoo Finance • 21h ago
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should KnowYahoo Finance report covering Novavax Inc. (NVAX) market action, institutional positioning, and fundamental catalysts.
Why NVAX Stock dropped -5.46% Today — RQD Quant Desk Flash
$9.53 -5.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $9.42
Novavax Inc. (NVAX) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $1.66B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on NVAX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is NVAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Novavax Inc. (NASDAQ: NVAX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $9.53 (-5.46% 1D, market cap $1.66B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, NVAX ranks #274 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does NVAX compare to REPL and MAZE in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), NVAX carries a Roarable D (49/100 RQD), trailing P/E of 3.9x, gross margin of 93.5%, and ROIC of 85.0%. By comparison, REPL (Replimune Group Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $1.67B) and MAZE (Maze Therapeutics Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.75B). Among the 5-stock peer group, NVAX leads on earnings multiple (3.9x) while NVAX leads on capital efficiency (85.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for NVAX?
▼
Per NVAX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001000694), Novavax Inc. generated $1.12B in revenue (+64.7% YoY), $440.3M in net income, and -$244.6M in free cash flow against $1.18B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $9.42 (-1.17%)🧬 Disciplined Float (+0.24% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-4.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NVAX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (49/100 Composite)
🔍 WHY NVAX SCORES 49/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+11/20 pts (22% of score)
FRED Regime × Technicals: 46% of 52W Range • RSI-14 at 45.3 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+11/20 pts (22% of score)
SEC Form 4 / 13F Thermometer: 55% Net Buy • Disciplined Float (+0.24% YoY Shares)
▼ #1 Drag / Risk Factor: Cash Engine Quality7/20 pts (-13 pt drag)
Capital intensity & 40.3% operating margin leave 13 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$12.82-10.8% Next Q
57
Q2 (-2Q)Grade C-$11.43-12.3% Next Q
54
Q3 (-1Q)Grade C-$10.02-4.9% Next Q
52
CurrentGrade D$9.53-5.4% Hist 90D α
49
Trajectory: C (57) → D (49)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a NVAX Turnaround Squeeze
While NVAX currently carries a cautious 49/100 (D) rating due to Cash Engine Quality (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.51) and Max Pain ($10.01) forces dealer call-delta covering toward $14.06.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.24% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NVAX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NVAX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NVAX Stock dropped -5.46% Today — RQD Quant Desk Flash
Novavax Inc. (NVAX) dropped -5.46% to $9.53, trading at 46% of its 52-week range ($6.2 – $13.39). Stretched risk/reward at 4x P/E (85% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 46% of its 52-week range ($6.2 – $13.39) with RSI-14 at 45.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $9.53 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 93.5% gross margin and $0 annual free cash flow.
Live NVAX Headlines & Catalysts
MARKET WIREInvesting.com • 1d ago
Why is Novavax stock surging today?Investing.com report covering Novavax Inc. (NVAX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRE24/7 Wall St. • 1d ago
Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady24/7 Wall St. report covering Novavax Inc. (NVAX) market action, institutional positioning, and fundamental catalysts.
RISK WATCHBenzinga • 1d ago
Novavax Stock Falls Back: What's Going On? - Novavax (NASDAQ:NVAX)Benzinga report covering Novavax Inc. (NVAX) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 1d ago
Novavax (NVAX) Stock Sinks As Market Gains: Here's WhyYahoo Finance report covering Novavax Inc. (NVAX) market action, institutional positioning, and fundamental catalysts.
CATALYST24/7 Wall St. • 1d ago
Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up24/7 Wall St. report covering Novavax Inc. (NVAX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Novavax (NVAX) Stock Could Be Above Fair Value As Plague Fears FadeYahoo Finance report covering Novavax Inc. (NVAX) market action, institutional positioning, and fundamental catalysts.
CATALYST24/7 Wall St. • 1d ago
Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies24/7 Wall St. report covering Novavax Inc. (NVAX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 4d ago
Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in EuropeNovavax (Nasdaq: NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax's COVID-19 vaccine, Nuvaxovi
CATALYSTYahoo • 5d ago
Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseNovavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NVAX)
- ✓Walkthrough of NVAX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NVAX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +18.68%🛡️ HOLDING TREND SUPPORT
2026-11-03O $10.47H $10.47L $9.53C $9.53VOL 4.06M
RES: $14.35SUP: $9.09SMA50: $10.51SMA200: $9.32
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NVAX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
-15.0%/yr Implied 5Y Growth
vs. +64.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on NVAX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NVAX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NVAX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NVAX)
Health Care Rank #274 of 1015
⚔️ REPL vs NVAX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NVAX vs. REPL, MAZE, IMCR, ALVO)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Novavax Inc. (NVAX) ranks #274 by composite RQD confidence (49/100, grade D) and #285 by equity capitalization ($1.66B). Within this direct 5-issuer industry benchmark cohort, NVAX leads on earnings valuation at 3.9x trailing P/E, while NVAX leads on capital efficiency and profitability with 85.0% ROIC and 93.5% gross margin. ALVO currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with NVAX at 49/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NVAX
ACTIVE
Novavax Inc. | D | 49/100 | 3.9x | 93.5% | 85.0% | -5.46% | $1.66B | Benchmark Subject |
| REPL Replimune Group Inc. | D | 50/100 | — | — | -35.0% | +10.68% | $1.67B | /repl-vs-nvax → |
| MAZE Maze Therapeutics Inc. | D- | 37/100 | — | — | -35.0% | -3.53% | $1.75B | /maze-vs-nvax → |
| IMCR Immunocore Holdings plc | E | 22/100 | — | 96.0% | -35.0% | -2.30% | $1.57B | /imcr-vs-nvax → |
| ALVO Alvotech | D+ | 52/100 | — | — | — | -3.66% | $1.82B | /alvo-vs-nvax → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001000694 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Novavax Inc. (NVAX) reported GAAP revenue of $1.12B (+64.7% vs. FY2024 revenue of $682.2M , and +14.2% cumulative change since FY2023) , GAAP net income of $440.3M, operating cash flow of -$244.6M, and free cash flow of -$244.6M (-180.3% YoY). On the balance sheet, NVAX closed FY2025 with $1.18B in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.12B | $440.3M | -$244.6M | -$244.6M | $1.18B | — |
| FY2024 (FY) | 2024-12-31 | $682.2M | -$187.5M | -$87.3M | -$87.3M | $1.56B | — |
| FY2023 (FY) | 2023-12-31 | $983.7M | -$545.1M | -$714.0M | -$714.0M | — | — |
3. NVAX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NVAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Novavax Inc. (NASDAQ: NVAX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $9.53 (-5.46% 1D, market cap $1.66B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, NVAX ranks #274 in composite RQD confidence.
How does NVAX compare to REPL and MAZE in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), NVAX carries a Roarable D (49/100 RQD), trailing P/E of 3.9x, gross margin of 93.5%, and ROIC of 85.0%. By comparison, REPL (Replimune Group Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $1.67B) and MAZE (Maze Therapeutics Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.75B). Among the 5-stock peer group, NVAX leads on earnings multiple (3.9x) while NVAX leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NVAX?
Per NVAX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001000694), Novavax Inc. generated $1.12B in revenue (+64.7% YoY), $440.3M in net income, and -$244.6M in free cash flow against $1.18B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NVAX trading relative to its 50-day, 200-day, and 52-week technical levels?
NVAX last traded at $9.53 (-5.46% on volume of 4,087,798 shares), positioning the stock -9.32% below its 50-day simple moving average ($10.51) and +2.25% above its 200-day simple moving average ($9.32). Across its 52-week range of $6.20 to $13.39, NVAX sits at the 46.3% percentile with a 14-day RSI of 45.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($8.34 to $10.72).
ROARABLE RATING BRIEF • RQD 49/100 (D)
✓ SEC XBRL & RQD VERIFIED
NVAX — Novavax Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Novavax Inc. (NVAX) earns a live Roarable RQD composite score of 49/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $9.53 (-5.46% 1D, market capitalization $1.66B).
- Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of 85.0%, gross margin of 93.5%, operating margin of 40.3%, and free cash flow yield of -14.17%.
- Whale 13F & Options Flow (10/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (11/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 5/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Novavax Inc. (NVAX) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry..7B. —: the specific product lines, customer base, and revenue model details. Per the market data, gross margin is 93.5%, operating margin 40.3%, and net margin 39.2%.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Novavax Inc. (NVAX) reported $1.12B in annual revenue (up from $682.2M in FY2024, +64.7% YoY) and $440.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($983.7M revenue, -$545.1M net income) through FY2025, NVAX scaled operating cash flow to -$244.6M and free cash flow to -$244.6M, backed by $1.18B in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D • RQD 49/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -14.17% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $6.20 – $13.39 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Investors must weigh 3.9x trailing P/E and 3.3x EV/EBITDA against 40.3% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Sector correlations are referenced in news headlines only, which mention peers Moderna, Pfizer, and BioNTech moving alongside NVAX. Watch for sector-wide vaccine policy and demand moves as a second-order driver, but the source does not quantify these dependencies.
- Key Question #1: Can NVAX sustain or expand its 40.3% operating margin and 85.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $1.12B and free cash flow of -$244.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is NVAX's 3.5x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
NVAX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Novavax Inc. (NVAX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 21h ago
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know Yahoo Finance report covering Novavax Inc. (NVAX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 1d ago
Why is Novavax stock surging today? Investing.com report covering Novavax Inc. (NVAX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE 24/7 Wall St. • 1d ago
Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady 24/7 Wall St. report covering Novavax Inc. (NVAX) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Benzinga • 1d ago
Novavax Stock Falls Back: What's Going On? - Novavax (NASDAQ:NVAX) Benzinga report covering Novavax Inc. (NVAX) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why Yahoo Finance report covering Novavax Inc. (NVAX) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST 24/7 Wall St. • 1d ago
Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up 24/7 Wall St. report covering Novavax Inc. (NVAX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Novavax (NVAX) Stock Could Be Above Fair Value As Plague Fears Fade Yahoo Finance report covering Novavax Inc. (NVAX) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST 24/7 Wall St. • 1d ago
Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies 24/7 Wall St. report covering Novavax Inc. (NVAX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
NVAX Bull vs. Bear Conversation Board — What's Your Call at $9.53?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NVAX 🐻 33% BEARISH CONVICTION
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH
🎯 Target: $12.90 (+28.0%)
📌 Pinned Debate ROIC of 85% and FY 2025 net income of $440.3M show strong reported profitability at a 3.9 TTM P/E.
Picked up a starter position in NVAX in my $100K Virtual Cash book at $10.08. ROIC of 85% and FY 2025 net income of $440.3M show strong reported profitability at a 3.9 TTM P/E.. Trading inside a $6.20–$13.39 52-week range with -14.17% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.
VolSurface_Trader 🐂 BULL
Both sides have a point here — NVAX's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH
🎯 Target: $8.16 (-19.0%)
Spot @ $10.08 Free cash flow of -14.17% yield and an Altman Z-Score of 0.2 signal cash burn and financial distress risk.
Here is the bear case nobody on the bull side wants to address on NVAX: Free cash flow of -14.17% yield and an Altman Z-Score of 0.2 signal cash burn and financial distress risk.. At 3.9x trailing P/E, even a small guidance miss in Biotechnology: Biological Products (No Diagnostic Substances) triggers a 12-15% air pocket.